I.V. NIKOLAEVA¹, L.R. GAYNATULLINA², S.E. GUSEVA², E.F. YUMAGULOVA², M.N. BELOVA² 

¹Kazan State Medical University, Kazan

²Republic Infectious Clinical Hospital named after Prof. A.F. Agafonov, Kazan

  Contact details:

Nikolaeva I.V. — MD, Professor, Head of the Department of Infectious Diseases

Address: 49 Butlerov St., Kazan, Russian Federation, 420110, tel.: +7 (843) 267-80-71, e-mail: irinanicolaeva@mail.ru

 The purpose — to study the etiological structure and antibiotic resistance of sepsis pathogens in patients with COVID-19.

Material and methods. A retrospective observational, uncontrolled study was conducted. We analyzed the results of an examination survey of 584 patients with severe and extremely severe forms of COVID-19 hospitalized at the Republic Clinical Infectious Diseases Hospital in Kazan from April 1, 2020 to October 1, 2022. Identification of the pathogen in blood and other biological materials was carried out using a Microflex LT Bruker mass spectrometer. The antibiotic sensitivity of the isolated bacterial strains was determined by the disk diffusion method using an ADAGIO analyzer (France).

Results. Various types of bacteria were isolated from the blood of 76 (13%) patients with severe and critical forms of COVID-19, including: A. baumannii (23.7%), K. pneumoniae (19.7%), S. haemolyticus (19.7%), S. aureus (7.9%), E. faecium (11.8%), E. faecalis (7.9%), E. coli (3.9%), R. planticola (2.6%), P. aeruginosa (2.6%), S. pneumoniae (2.6%), S. maltophilia (1.3%), and B. cereus (1.3%). In 15 patients (19.7%) associations of 2–3 types of bacteria were isolated from the blood. A. baumannii isolates were resistant to carbapenems (94.5%), fluoroquinolones and aminoglycosides (100%), and trimethoprim-sulfamethoxazole (83.3%) strains. K. рneumoniae strains were resistant to carbapenems (60%), cephalosporins (cefixime, ceftazidime) (73.3%), fluoroquinolones (ciprofloxacin) (80%), aminoglycosides (60%), and semisynthetic penicillins (100%). 33.3% of S. aureus strains were resistant to trimethoprim-sulfamethoxazole, 16.7% — to oxacillin, erythromycin and gentamicin. Resistance of S. haemolyticus to trimethoprim-sulfamethoxazole was detected in 86.7%, to erythromycin — in 80%, to norfloxacin — in 50% of strains. 93.3% of S. haemolyticus strains were methicillin-resistant. 88.9% of E. faecium strains were resistant to ampicillin, 22.2% to tigecycline, 11.1% to linezolid. 50% of E. faecalis strains were resistant to norfloxacin, 16.7% of strains were resistant to amoxicillin, ampicillin and piperacillin. P. aeruginosa 50% of strains were resistant to levofloxacin. R. planticola was resistant to all antibiotics tested. S. maltophilia demonstrated sensitivity to co-trimoxazole only with increased exposure.

Conclusion. Bacterial sepsis was diagnosed in 13% of severe and extremely severe patients with COVID-19. The etiological structure of sepsis includes a wide range of pathogens with a predominance of multi-resistant bacteria from the group of ESKAPE pathogens. Data on the etiological structure and antibiotic resistance of isolated pathogens should be taken into account for the rational use of antimicrobial drugs in the treatment of sepsis in patients with COVID-19.

Key words: COVID-19, sepsis, antibiotic resistance.

REFERENCES

1. Sluchai COVID-19. Informatsionnaya panel’ VOZ po COVID-19 [COVID-19 cases. WHO COVID-19 dashboard], available at: https://data.who.int/dashboards/covid19/cases?n=c]
2. Gu X., Zhou F., Wang Y. et al. Respiratory viral sepsis: epidemiology, pathophysiology, diagnosis and treatment. Eur. Res. Rev, 2020, vol. 29 (157), 200038. DOI: 10.1183/16000617.0038-2020
3. Hoque M.N., Akter S., Mishu I.D. et al. Microbial co-infections in COVID-19: Associated microbiota and underlying mechanisms of pathogenesis. Microb. Pathog, 2021, vol. 156, 104941. DOI: 10.1016/j.micpath.2021.104941
4. Singer M. et al. The Third International consensus definitions for sepsis and septic shock. (Sepsis-3). JAMA, 2016, vol. 315 (8), pp. 801–810.
5. Zhang G., Hu C., Luo L, et al. Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China. J. Clin. Virol, 2020, vol. 127, 104364. DOI: 10.1016/j.jcv.2020.104364
6. Wang L., He W., Yu X., Hu D., Bao M., Liu H. et al. Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up. J. Inf, 2020, vol. 80 (6), pp. 639–645. DOI: 10.1016/j.jinf.2020.03.019
7. Martins-Filho P.R., Tavares C.S.S, Santos V.S. Factors associated with mortality in patients with COVID-19. A quantitative evidence synthesis of clinical and laboratory data. Eur. J. Int. Med, 2020, vol. 76, pp. 97–99. DOI: 10.1016/j.ejim.2020.04.043
8. Pasquini Z., Barocci I., Brescini L. et al. Bloodstream infections in the COVID-19 era: results from an Italian multi-centre study. Int. J. Infect. Dis, 2021, vol. 111, pp. 31–36. DOI: 10.1016/j.ijid.2021.07.065
9. Heubner L., Hattenhauer S.., Güldner A. et al. Characteristics and outcomes of sepsis patients with and without COVID-19. J. Infect. Pub. Health, 2022, vol. 15 (6), pp. 670–676. DOI: 10.1016/j.jiph.2022.05.008
10. Shappell C.N., Klompas M., Kanjilal S. et al. Prevalence, clinical characteristics, and outcomes of sepsis caused by severe acute respiratory syndrome coronavirus 2 versus other pathogens in hospitalized patients with COVID-19. Crit. Care Explor, 2022, vol. 4 (5), p. e0703. DOI: 10.1097/CCE.0000000000000703
11. Puzniak L.A., Bauer K.A., Yu K.C. et al. A multicenter evaluation of antibacterial use in hospitalized patients through the SARS-Cov-2 pandemic waves. BMC Infect. Dis, 2023, vol. 23 (1), p. 117. DOI: 10.1186/s12879-023-08042-0
12. Walsh T.J., Bright R.A., Ahuja A. et al. Meeting the challenges of sepsis in severe coronavirus disease 2019: a call to arms. Open Forum Infect. Dis, 2022, vol. 10 (1), pp. ofac645. DOI: 10.1093/ofid/ofac645
13. Bartoszewicz M., Czaban S.L., Bartoszewicz K., Kuźmiuk D., Ładny J.R. Bacterial bloodstream infection in critically ill patients with COVID-19: a retrospective cohort study. Ther. Adv. Infect. Dis, 2023, vol. 10, 20499361231207178. DOI: 10.1177/20499361231207178
14. Avdeev S.N., Adamyan L.V., Alekseeva E.I. Vremennye metodicheskie rekomendatsii “Profilaktika, diagnostika i lechenie novoy koronavirusnoy infektsii (COVID-19)”. Versiya 13 (14.10.2020). MZ RF [Temporary guidelines “Prevention, diagnosis and treatment of new coronavirus infection (COVID-19).” Version 13 (10/14/2020). Ministry of Health of the Russian Federation].
15. Avdeev S.N., Adamyan L.V., Alekseeva E.I. Vremennye metodicheskie rekomendatsii “Profilaktika, diagnostika i lechenie novoy koronavirusnoy infektsii (COVID-19)”. Versiya 14 (27.12.2021). MZ RF [Temporary guidelines “Prevention, diagnosis and treatment of new coronavirus infection (COVID-19).” Version 14 (12/27/2021). Ministry of Health of the Russian Federation].
16. Moreno-García E., Puerta-Alcalde P., Letona L. et al. COVID-19-researcher group. Bacterial co-infection at hospital admission in patients with COVID-19. Int. J. Infect. Dis, 2022, vol. 118, pp. 197–202. DOI: 10.1016/j.ijid.2022.03.003
17. Karoli N.A., Rebrov A.P. Frequency and nature of bacterial infection in patients with COVID-19. Yuzhno-Rossiyskiy zhurnal terapevticheskoy praktiki, 2023, vol. 4, no. 1, pp. 28–39 (in Russ.). DOI: 10.21886/2712-8156-2023-4-1-28-39
18. Protonotariou E., Mantzana P., Meletis G. et al. Microbiological characteristics of bacteremias among COVID-19 hospitalized patients in a tertiary referral hospital in Northern Greece during the second epidemic wave. FEMS Microbes, 2021, vol. 2, xtab021. DOI: 10.1093/femsmc/xtab021
19. Elzi L., Babouee B., Vögeli N., Laffer R. et al. How to discriminate contamination from bloodstream infection due to coagulase-negative staphylococci: a prospective study with 654 patients. Clin. Mcrobiol. Infect, 2012, vol. 18 (9), pp. E355–361. DOI: 10.1111/j.1469-0691.2012.03964.x
20. Edbert D., Mertaniasih N.M., Endraswari P.D. Phenotypic analyses of blood culture contaminants in COVID-19 intensive care unit using hierarchical clustering during the pandemic first wave in Surabaya. Path. Lab. Med. Int, 2022, vol. 14, pp. 7–13.
21. Salimiyanrizi K., Farsiani H. Raoultella infections from clinical to laboratory — update & literature review. Rev. Clin. Med, 2022, vol. 9 (4), pp. 159–171.
22. Abed N., Hussein A., Salaheldine S. et al. Outcome of unimicrobial versus polymicrobial sepsis. Crit. Care, 2010, vol. 14 (1), p. 62. DOI: 10.1186/cc8294
23. Wu C.P., Adhi F., Highland K. Recognition and management of respiratory co-infection and secondary bacterial pneumonia in patients with COVID-19. Cleve. Clin. J. Med, 2020, vol. 87 (11), pp. 659–663. DOI: 10.3949/ccjm.87a.ccc015